JP2015513903A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015513903A5 JP2015513903A5 JP2015503318A JP2015503318A JP2015513903A5 JP 2015513903 A5 JP2015513903 A5 JP 2015513903A5 JP 2015503318 A JP2015503318 A JP 2015503318A JP 2015503318 A JP2015503318 A JP 2015503318A JP 2015513903 A5 JP2015513903 A5 JP 2015513903A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- kallidin
- antibody
- arg
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018218861A JP6912441B2 (ja) | 2012-03-28 | 2018-11-22 | ブラジキニンｂ１受容体リガンドに対する抗体 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261616845P | 2012-03-28 | 2012-03-28 | |
| US61/616,845 | 2012-03-28 | ||
| FR1350953 | 2013-02-04 | ||
| FR1350953 | 2013-02-04 | ||
| PCT/US2013/031836 WO2013148296A1 (en) | 2012-03-28 | 2013-03-15 | Antibodies to bradykinin b1 receptor ligands |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018218861A Division JP6912441B2 (ja) | 2012-03-28 | 2018-11-22 | ブラジキニンｂ１受容体リガンドに対する抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015513903A JP2015513903A (ja) | 2015-05-18 |
| JP2015513903A5 true JP2015513903A5 (enExample) | 2016-04-07 |
| JP6779012B2 JP6779012B2 (ja) | 2020-11-04 |
Family
ID=49261064
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015503318A Active JP6779012B2 (ja) | 2012-03-28 | 2013-03-15 | ブラジキニンｂ１受容体リガンドに対する抗体 |
| JP2018218861A Active JP6912441B2 (ja) | 2012-03-28 | 2018-11-22 | ブラジキニンｂ１受容体リガンドに対する抗体 |
| JP2021112483A Active JP7411609B2 (ja) | 2012-03-28 | 2021-07-07 | ブラジキニンｂ１受容体リガンドに対する抗体 |
| JP2023216462A Pending JP2024038036A (ja) | 2012-03-28 | 2023-12-22 | ブラジキニンｂ１受容体リガンドに対する抗体 |
| JP2025104387A Pending JP2025134874A (ja) | 2012-03-28 | 2025-06-20 | ブラジキニンｂ１受容体リガンドに対する抗体 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018218861A Active JP6912441B2 (ja) | 2012-03-28 | 2018-11-22 | ブラジキニンｂ１受容体リガンドに対する抗体 |
| JP2021112483A Active JP7411609B2 (ja) | 2012-03-28 | 2021-07-07 | ブラジキニンｂ１受容体リガンドに対する抗体 |
| JP2023216462A Pending JP2024038036A (ja) | 2012-03-28 | 2023-12-22 | ブラジキニンｂ１受容体リガンドに対する抗体 |
| JP2025104387A Pending JP2025134874A (ja) | 2012-03-28 | 2025-06-20 | ブラジキニンｂ１受容体リガンドに対する抗体 |
Country Status (38)
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104334578B (zh) * | 2012-03-28 | 2021-10-08 | 赛诺菲 | 缓激肽b1受体配体的抗体 |
| PE20152004A1 (es) | 2013-03-13 | 2016-02-07 | Prothena Biosciences Ltd | Inmunoterapia tau |
| CN105504049B (zh) * | 2014-09-26 | 2019-07-05 | 艾托金生物医药（苏州）有限公司 | 宫颈癌相关的hpv e7蛋白单克隆抗体及其应用 |
| EP3390439B1 (en) | 2015-12-15 | 2025-03-12 | Takeda Pharmaceutical Company Limited | Peptide quantitation assay for differentiating full-length high molecular weight kininogen (hmwk) and cleaved hmwk |
| US11299751B2 (en) | 2016-04-29 | 2022-04-12 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| WO2017189959A1 (en) | 2016-04-29 | 2017-11-02 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| SG11201809331RA (en) | 2016-05-02 | 2018-11-29 | Prothena Biosciences Ltd | Antibodies recognizing tau |
| EP3452507B1 (en) | 2016-05-02 | 2022-10-19 | Prothena Biosciences Limited | Tau immunotherapy |
| PE20190261A1 (es) | 2016-05-02 | 2019-02-25 | Prothena Biosciences Ltd | Anticuerpos que reconocen tau |
| JOP20190100A1 (ar) | 2016-11-19 | 2019-05-01 | Potenza Therapeutics Inc | بروتينات ربط مولد ضد مضاد لـ gitr وطرق استخدامها |
| IL270375B2 (en) | 2017-05-02 | 2024-12-01 | Prothena Biosciences Ltd | Antibodies recognizing tau |
| KR102844399B1 (ko) * | 2017-05-08 | 2025-08-11 | 아디맵 엘엘씨 | 항-cd3-결합 도메인 및 이를 포함하는 항체, 및 이를 생성하고 사용하는 방법 |
| TW201945026A (zh) * | 2018-01-29 | 2019-12-01 | 美商希拉諾斯醫療公司 | 結合erfe之抗體及使用方法 |
| AU2020231366A1 (en) | 2019-03-03 | 2021-08-12 | Prothena Biosciences Limited | Antibodies recognizing tau |
| CN119306824B (zh) * | 2024-10-08 | 2025-09-26 | 江苏埃尔迪生物科技有限公司 | 一种全价展示scFv的通用型M13噬菌体探针及其构建方法和应用 |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| WO1989012624A2 (en) | 1988-06-14 | 1989-12-28 | Cetus Corporation | Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom |
| US6780613B1 (en) | 1988-10-28 | 2004-08-24 | Genentech, Inc. | Growth hormone variants |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| IE63847B1 (en) | 1989-05-05 | 1995-06-14 | Res Dev Foundation | A novel antibody delivery system for biological response modifiers |
| US5460785A (en) | 1989-08-09 | 1995-10-24 | Rhomed Incorporated | Direct labeling of antibodies and other protein with metal ions |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| US5314995A (en) | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
| DE69127749T2 (de) | 1990-03-20 | 1998-04-16 | The Trustees Of Columbia University In The City Of New York, New York, N.Y. | Chimäre antikörper mit rezeptor-bindenden liganden anstelle ihrer konstanten region |
| DE69133036T2 (de) | 1990-11-09 | 2003-02-06 | Stephen D. Gillies | Cytokine immunokonjugate |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| GB9422383D0 (en) | 1994-11-05 | 1995-01-04 | Wellcome Found | Antibodies |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| GB9524973D0 (en) | 1995-12-06 | 1996-02-07 | Lynxvale Ltd | Viral vectors |
| CA2262405A1 (en) | 1996-08-02 | 1998-02-12 | Bristol-Myers Squibb Company | A method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis |
| WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| AU736549B2 (en) | 1997-05-21 | 2001-08-02 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Method for the production of non-immunogenic proteins |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| US6242195B1 (en) | 1998-04-02 | 2001-06-05 | Genentech, Inc. | Methods for determining binding of an analyte to a receptor |
| US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
| CA2323757C (en) | 1998-04-02 | 2011-08-02 | Genentech, Inc. | Antibody variants and fragments thereof |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| CA2341029A1 (en) | 1998-08-17 | 2000-02-24 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
| EP1006183A1 (en) | 1998-12-03 | 2000-06-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Recombinant soluble Fc receptors |
| CA2342967A1 (en) | 1998-12-08 | 2000-06-15 | Biovation Limited | Modifying protein immunogenicity |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| HUP0104865A3 (en) | 1999-01-15 | 2004-07-28 | Genentech Inc | Polypeptide variants with altered effector function |
| GB0029407D0 (en) | 2000-12-01 | 2001-01-17 | Affitech As | Product |
| PT1355919E (pt) | 2000-12-12 | 2011-03-02 | Medimmune Llc | Moléculas com semivida longa, composições que as contêm e suas utilizações |
| US20040002587A1 (en) | 2002-02-20 | 2004-01-01 | Watkins Jeffry D. | Fc region variants |
| EP1487879B1 (en) | 2002-03-01 | 2012-12-26 | Immunomedics, Inc. | Bispecific antibody point mutations for enhancing rate of clearance |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| AU2003262650B2 (en) | 2002-08-14 | 2009-10-29 | Macrogenics, Inc. | FcgammaRIIB-specific antibodies and methods of use thereof |
| CA2832136C (en) | 2002-09-27 | 2015-11-17 | Xencor | Optimized fc variants and methods for their generation |
| JP4768439B2 (ja) | 2002-10-15 | 2011-09-07 | アボット バイオセラピューティクス コーポレイション | 変異誘発による抗体のＦｃＲｎ結合親和力又は血清半減期の改変 |
| AU2004204494B2 (en) | 2003-01-09 | 2011-09-29 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| NZ545776A (en) | 2003-08-22 | 2009-05-31 | Biogen Idec Inc | Improved antibodies having altered effector function and methods for making the same |
| GB0324368D0 (en) | 2003-10-17 | 2003-11-19 | Univ Cambridge Tech | Polypeptides including modified constant regions |
| JP2008504002A (ja) | 2003-11-12 | 2008-02-14 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 新生児Ｆｃレセプター（ＦｃＲｎ）結合ポリペプチド改変体、ダイマーＦｃ結合タンパク質、およびそれらに関連する方法 |
| WO2005077981A2 (en) | 2003-12-22 | 2005-08-25 | Xencor, Inc. | Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES |
| JP4762156B2 (ja) | 2004-01-12 | 2011-08-31 | アプライド モレキュラー エボリューション，インコーポレイテッド | Ｆｃ領域変異体 |
| EP1737890A2 (en) | 2004-03-24 | 2007-01-03 | Xencor, Inc. | Immunoglobulin variants outside the fc region |
| WO2005123780A2 (en) | 2004-04-09 | 2005-12-29 | Protein Design Labs, Inc. | Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis |
| WO2006085967A2 (en) | 2004-07-09 | 2006-08-17 | Xencor, Inc. | OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS |
| KR100863776B1 (ko) | 2004-07-15 | 2008-10-16 | 젠코어 인코포레이티드 | 최적화된 Ｆｃ 변이체 |
| WO2006047350A2 (en) | 2004-10-21 | 2006-05-04 | Xencor, Inc. | IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION |
| JP2008543810A (ja) | 2005-06-14 | 2008-12-04 | サイトス バイオテクノロジー アーゲー | 抗原コンジュゲート及びその使用 |
| US8460364B2 (en) | 2006-07-20 | 2013-06-11 | Orbusneich Medical, Inc. | Bioabsorbable polymeric medical device |
| JP2010509920A (ja) * | 2006-11-15 | 2010-04-02 | メダレックス インコーポレーティッド | Ｂｔｌａに対するヒトモノクローナル抗体および使用方法 |
| WO2008151204A1 (en) | 2007-06-04 | 2008-12-11 | Sequent Medical Inc. | Methods and devices for treatment of vascular defects |
| CN101820911B (zh) * | 2007-06-12 | 2015-05-06 | Ac免疫有限公司 | β淀粉样蛋白的人源化抗体 |
| KR20140117638A (ko) | 2007-08-29 | 2014-10-07 | 사노피 | 인간화된 항-ｃｘｃｒ5 항체, 이의 유도체 및 이들의 용도 |
| DK2224954T3 (en) * | 2007-11-07 | 2014-03-03 | Celldex Therapeutics Inc | Antibodies that bind human dendritic and epithelial cell 205 (DEC-205) |
| EP2420245A1 (en) * | 2010-08-18 | 2012-02-22 | Max-Delbrück-Centrum Für Molekulare Medizin | Therapeutic use of agonists or antagonists of bradykinin receptor 1 or 2, for modulation collateral blood vessel growth |
| CN104334578B (zh) * | 2012-03-28 | 2021-10-08 | 赛诺菲 | 缓激肽b1受体配体的抗体 |
-
2013
- 2013-03-15 CN CN201380027405.8A patent/CN104334578B/zh active Active
- 2013-03-15 JP JP2015503318A patent/JP6779012B2/ja active Active
- 2013-03-15 PL PL13715049T patent/PL2831113T3/pl unknown
- 2013-03-15 DK DK13715049.6T patent/DK2831113T3/en active
- 2013-03-15 CA CA2868353A patent/CA2868353C/en active Active
- 2013-03-15 US US14/382,798 patent/US9376494B2/en active Active
- 2013-03-15 TW TW102109162A patent/TWI605060B/zh active
- 2013-03-15 SG SG11201405162YA patent/SG11201405162YA/en unknown
- 2013-03-15 SI SI201331066T patent/SI2831113T1/en unknown
- 2013-03-15 MY MYPI2014002482A patent/MY166157A/en unknown
- 2013-03-15 UA UAA201411667A patent/UA117097C2/uk unknown
- 2013-03-15 KR KR1020147029192A patent/KR102035882B1/ko active Active
- 2013-03-15 AR ARP130100847 patent/AR090352A1/es unknown
- 2013-03-15 MX MX2014011688A patent/MX361874B/es active IP Right Grant
- 2013-03-15 UY UY34682A patent/UY34682A/es not_active Application Discontinuation
- 2013-03-15 SG SG10201702396QA patent/SG10201702396QA/en unknown
- 2013-03-15 EP EP17179380.5A patent/EP3246339B1/en active Active
- 2013-03-15 AU AU2013240242A patent/AU2013240242B2/en not_active Ceased
- 2013-03-15 KR KR1020207028912A patent/KR102367723B1/ko active Active
- 2013-03-15 MA MA37407A patent/MA37407B1/fr unknown
- 2013-03-15 CN CN202510415465.1A patent/CN120441698A/zh active Pending
- 2013-03-15 CN CN202111098640.7A patent/CN113773385B/zh active Active
- 2013-03-15 EA EA201491784A patent/EA201491784A1/ru unknown
- 2013-03-15 KR KR1020197030406A patent/KR102166083B1/ko active Active
- 2013-03-15 LT LTEP13715049.6T patent/LT2831113T/lt unknown
- 2013-03-15 HU HUE13715049A patent/HUE037720T2/hu unknown
- 2013-03-15 BR BR112014024282A patent/BR112014024282A2/pt not_active IP Right Cessation
- 2013-03-15 WO PCT/US2013/031836 patent/WO2013148296A1/en not_active Ceased
- 2013-03-15 PT PT137150496T patent/PT2831113T/pt unknown
- 2013-03-15 PE PE2014001473A patent/PE20142170A1/es active IP Right Grant
- 2013-03-15 MY MYPI2018701130A patent/MY184037A/en unknown
- 2013-03-15 DK DK17179380.5T patent/DK3246339T3/da active
- 2013-03-15 TR TR2018/08486T patent/TR201808486T4/tr unknown
- 2013-03-15 KR KR1020227005891A patent/KR20220031728A/ko not_active Ceased
- 2013-03-15 NZ NZ631543A patent/NZ631543A/en not_active IP Right Cessation
- 2013-03-15 RS RS20180704A patent/RS57413B1/sr unknown
- 2013-03-15 HR HRP20180928TT patent/HRP20180928T1/hr unknown
- 2013-03-15 ES ES13715049.6T patent/ES2673869T3/es active Active
- 2013-03-15 EP EP13715049.6A patent/EP2831113B1/en active Active
-
2014
- 2014-09-03 DO DO2014000199A patent/DOP2014000199A/es unknown
- 2014-09-03 PH PH12014501970A patent/PH12014501970A1/en unknown
- 2014-09-12 GT GT201400192A patent/GT201400192A/es unknown
- 2014-09-23 CR CR20140440A patent/CR20140440A/es unknown
- 2014-09-23 IL IL234830A patent/IL234830B/en active IP Right Grant
- 2014-09-26 MX MX2018015914A patent/MX2018015914A/es unknown
- 2014-09-26 CL CL2014002590A patent/CL2014002590A1/es unknown
- 2014-10-23 CO CO14234406A patent/CO7111293A2/es unknown
-
2016
- 2016-05-25 US US15/163,883 patent/US9879079B2/en active Active
-
2017
- 2017-11-30 CL CL2017003039A patent/CL2017003039A1/es unknown
- 2017-12-18 US US15/844,883 patent/US10465002B2/en active Active
-
2018
- 2018-05-03 AU AU2018203081A patent/AU2018203081A1/en not_active Abandoned
- 2018-06-14 CY CY20181100623T patent/CY1121466T1/el unknown
- 2018-11-22 JP JP2018218861A patent/JP6912441B2/ja active Active
-
2019
- 2019-09-24 US US16/580,603 patent/US20200115441A1/en not_active Abandoned
-
2021
- 2021-07-07 JP JP2021112483A patent/JP7411609B2/ja active Active
-
2022
- 2022-12-09 US US18/063,981 patent/US20230399388A1/en active Pending
-
2023
- 2023-12-22 JP JP2023216462A patent/JP2024038036A/ja active Pending
-
2025
- 2025-06-20 JP JP2025104387A patent/JP2025134874A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015513903A5 (enExample) | ||
| JP2022105178A (ja) | 黄色ブドウ球菌（ｓｔａｐｈｙｌｏｃｏｃｃｕｓ ａｕｒｅｕｓ）感染症を治療および予防するための組成物および方法 | |
| FI3487882T3 (fi) | Gprc5d-vasta-aineita, bispesifisiä antigeeniä sitovia molekyylejä, jotka sitovat gprc5d:tä ja cd3:a, sekä niiden käyttötapoja | |
| SI2831113T1 (en) | Antibodies to bradykinin b1 receptor ligands | |
| JP2016538876A5 (enExample) | ||
| RU2019111722A (ru) | Антитела против siglec-15 и способы их применения | |
| RU2013102225A (ru) | АНТИТЕЛА ПРОТИВ Axl И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
| RU2014109039A (ru) | Биспецифические антигенсвязывающие молекулы | |
| US10654915B2 (en) | Antibodies useful in passive influenza immunization | |
| RU2018102606A (ru) | Молекулы, связывающиеся с psl pseudomonas, и пути их применения | |
| RU2012137498A (ru) | Фармацевтическая композиция для лечения и/или профилактики рака | |
| RU2013141077A (ru) | Антигенсвязывающие белки | |
| RU2016151265A (ru) | Антитела, направленные на cd127 | |
| JP2010526028A5 (enExample) | ||
| JP2014169326A5 (enExample) | ||
| JP2014502955A5 (enExample) | ||
| RU2016137256A (ru) | АНТИТЕЛА К ФАКТОРУ КОМПЛЕМЕНТА Bb | |
| RU2016137110A (ru) | Антитела к компоненту комплемента с5 | |
| JP2012531922A5 (ja) | Ｔｏｌｌ様受容体２へのヒト化抗体またはその抗原結合部位 | |
| JP2013520984A5 (enExample) | ||
| RU2013102073A (ru) | Антитела, подходящие для пассивной иммунизации против гриппа | |
| RU2019134462A (ru) | Антитела, связывающиеся с steap-1 | |
| JP2016520595A5 (enExample) | ||
| RU2014140116A (ru) | Антитела против pdgf-c | |
| RU2017104638A (ru) | Нейтрализующие антитела к вирусу гриппа B и пути их применения |